Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020.
Harvala H., Mehew J., Robb ML., Ijaz S., Dicks S., Patel M., Watkins N., Simmonds P., Brooks T., Johnson R., Gopal R., Roberts DJ., Zambon M., NHS Blood and Transplant Convalescent Plasma Testing Group None.
Serological reactivity was analysed in plasma from 436 individuals with a history of disease compatible with COVID-19, including 256 who had been laboratory-confirmed with SARS-CoV-2 infection. Over 99% of laboratory-confirmed cases developed a measurable antibody response (254/256) and 88% harboured neutralising antibodies (226/256). Antibody levels declined over 3 months following diagnosis, emphasising the importance of the timing of convalescent plasma collections. Binding antibody measurements can inform selection of convalescent plasma donors with high neutralising antibody levels.